

PE-CONJUGATED MONOCLONAL ANTIBODY EFFECTIVE DATE: 2015-12-21

1 Product and Company Identification

1.1 Product Name/Catalog Number:

Product Name	Catalog Number
Mouse IgG1, kappa Isotype Control Antibody, Clone X40, PE	60120PE
Anti-Human CD34 Antibody, Clone 8G12, PE	60121PE
Anti-Human CD25 Antibody, Clone 2A3, PE	60153PE

1.2 Product Use: Flow Cytometry

1.3 Manufacturer/Supplier: STEMCELL Technologies Inc.

Suite 500-1618 Station Street

Vancouver, British Columbia V6A 1B6 Canada

1.4 In Case of Emergency Call: 1-800-667-0322

2 Hazards Identification

2.1 Classification of the substance or mixture

Not a hazardous substance or mixture according to the Globally Harmonized System (GHS).

2.2 Label elements

Not a hazardous substance or mixture.

2.3 Other hazards No data available

3 Composition / Information on Ingredients

3.1 Substances

Hazardous Components (Chemical Name)	CAS#	Concentration	EC#
Sodium azide	26628-22-8	0.1%	247-852-1

4 First Aid Measures

4.1 Description of first aid measures

4.1.1 If inhaled

If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

4.1.2 In case of skin contact

Wash off with soap and plenty of water. Consult a physician.

4.1.3 In case of eye contact

Flush eyes with water as a precaution.

4.1.4 If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2 Most important symptoms and effects, both acute and delayed



PE-CONJUGATED MONOCLONAL ANTIBODY

EFFECTIVE DATE: 2015-12-21

The most important known symptoms and effects are described in section 2.2 and/or in section 11.

4.3 Indication of any immediate medical attention and special treatment needed

No data available

5 Fire Fighting Measures

5.1 Extinguishing Media

5.1.1 Suitable Extinguishing Media

Use alcohol-resistant foam, carbon dioxide, water, or dry chemical spray.

5.1.2 Unsuitable Extinguishing Media

No data available

5.2 Special hazards arising from the substance or mixture

5.2.1 Flammable Properties and Hazards

No data available

5.2.2 Flash Pt

No data available

5.2.3 Autoignition Pt

No data available

5.2.4 Explosive Limits

LEL: No data available UEL: No data available

5.2.5 Hazardous Combustion Products

No data available

5.3 Fire Fighting Instructions

As in any fire, wear self-contained breathing apparatus pressure-demand (NIOSH approved or equivalent), and full protective gear to prevent contact with skin and eyes.

6 Accidental Release Measures

6.1 Personal precautions, protective equipment and emergency procedures

Avoid breathing vapors, mist or gas.

For personal protection see section 8.

6.2 Environmental precautions

No special environmental precautions required.

6.3 Methods and materials for containment and cleaning up

Keep in suitable, closed containers for disposal.

7 Handling and Storage

7.1 Precautions for safe handling

For precautions see section 2.2.



PE-CONJUGATED MONOCLONAL ANTIBODY EFFECTIVE DATE: 2015-12-21

7.2 Conditions for safe storage

Keep container tightly closed in a dry and well-ventilated place.

8 Exposure Controls/Personal Protection

8.1 Exposure limits

Component	CAS#	Value	Control parameters	Basis	
Sodium azide	26628-22-8	STEL	0.3 mg/m ³	UK. EH40 WEL – Workplace Exposure Limits	
	Remarks	Can be absorbed through skin. The assigned substances are those for which there are concerns that dermal absorption will lead to systemic toxicity.			
		TWA	0.1 mg/m ³	UK. EH40 WEL – Workplace Exposure Limits	
		Can be absorbed through skin. The assigned substances are those for which there are concerns that dermal absorption will lead to systemic toxicity.			
		TWA	0.1 mg/m ³	Europe. Commission Directive 2000/39/EC establishing a first list of indicative occupational exposure limit values	
		Identifies the possibility of significant uptake through the skin Indicative			
		STEL	0.3 mg/m ³	Europe. Commission Directive 2000/39/EC establishing a first list of indicative occupational exposure limit values	
		Identifies the possibility of significant uptake through the skin Indicative			

8.2 Engineering controls

Use mechanical exhaust or laboratory fumehood to avoid exposure.

8.3 Personal protective equipment

8.3.1 Eye/face protection

Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

8.3.2 Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Impervious clothing. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

8.3.3 Respiratory protection

Respiratory protection not required. For nuisance exposures use type OV/AG (US) or type ABEK (EU EN 14387) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

8.3.4 General hygiene considerations

General industrial hygiene practice.

8.3.5 Environmental exposure controls

No data available

Page 4 of 7



Safety Data Sheet

PE-CONJUGATED MONOCLONAL ANTIBODY EFFECTIVE DATE: 2015-12-21

9 Physical and Chemical Properties

9.1 Information on basic physical and chemical properties

Clear liquid **Appearance** Odour No data available Odour threshold No data available Hq No data available Melting point/freezing point No data available Boiling point/boiling range No data available Flash point No data available Evaporation rate No data available Flammability (solid, gas) No data available Upper/lower flammability or explosive limits No data available Vapour pressure No data available Vapour density No data available Relative density No data available Solubility No data available Partition coefficient: n-octanol/water No data available Auto-ignition temperature No data available Decomposition temperature No data available Viscosity No data available

10 Stability and Reactivity

10.1	Reactivity	No data available
10.2	Chemical stability	No data available
10.3	Possibility of hazardous reactions	No data available
10.4	Conditions to avoid	No data available
10.5	Incompatible materials	No data available
10.6	Hazardous decomposition products	No data available

11 Toxicological Information

11.1 Acute toxicity

Oral: No data available
Inhalation: No data available
Dermal: No data available
Other: No data available

11.2 Skin corrosion/irritation

No data available

11.3 Serious eye damage/eye irritation

No data available

11.4 Respiratory and/or skin sensitization



PE-CONJUGATED MONOCLONAL ANTIBODY EFFECTIVE DATE: 2015-12-21

No data available

11.5 Germ cell mutagenicity

No data available

11.6 Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

NTP: No component of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is

identified as a carcinogen or potential carcinogen by OSHA.

11.7 Reproductive toxicity

No data available

11.8 Specific target organ toxicity - single exposure

No data available

11.9 Specific target organ toxicity - repeated exposure

No data available

11.10 Aspiration hazard

No data available

11.11 Potential health effects

Inhalation: May be harmful if inhaled. May cause respiratory tract irritation.

Ingestion: May be harmful if swallowed.

Skin: May be harmful if absorbed through skin. May cause skin irritation.

Eyes: May cause eye irritation.

11.12 Signs and symptoms of exposure

To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

Liver - Irregularities - Based on Human Evidence (Sodium azide)

11.13 RTECS # No data available

12 Ecological Information

12.1 Toxicity No data available
12.2 Persistence and degradability No data available
12.3 Bioaccumulative potential No data available
12.4 Mobility in soil No data available

Harmful to aquatic life.

13 Disposal Considerations

13.1 Waste disposal method

12.5 Other adverse effects

Offer surplus and non-recyclable solutions to a licensed disposal company.

13.2 Contaminated packaging

Dispose of as unused product.

PEconjmAb_06-SDS_GHS Page 5 of 7



PE-CONJUGATED MONOCLONAL ANTIBODY EFFECTIVE DATE: 2015-12-21

14 Transport Information

14.1 UN number DOT Not dangerous goods

ADR/RID 3082 IMDG 3082 IATA 3082

14.2 UN proper shipping name DOT Not dangerous goods

ADR/RID ENVIRONMENTALLY HAZARDOUS SUBSTANCE,

LIQUID, N.O.S. (Sodium azide)

IMDG ENVIRONMENTALLY HAZARDOUS SUBSTANCE,

LIQUID, N.O.S. (Sodium azide)

IATA Environmentally hazardous substance, liquid, n.o.s.

(Sodium azide)

14.3 Transport hazard class(es) DOT Not dangerous goods

ADR/RID 9 IMDG 9 IATA 9

14.4 Packing group DOT Not dangerous goods

ADR/RID III IMDG III IATA III

14.5 Environmental hazards DOT Not dangerous goods

ADR/RID Yes

IMDG Marine pollutant: Yes

IATA Yes

14.6 Special precautions No data available

14.7 Further information

EHS-Mark required (ADR 2.2.9.1.10, IMDG code 2.10.3) for single packaging and combination packaging containing inner packaging with Dangerous Goods > 5 L for liquids or > 5 kg for solids.

15 Regulatory Information

15.1 USA

SARA 302 Components:

The following components are subject to reporting levels established by SARA Title III, Section 302:

Component CAS # Revision Date Sodium azide 26628-22-8 2007-07-01

SARA 313 Components:

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312:

No SARA Hazards

Massachusetts Right To Know Components

PEconjmAb_06-SDS_GHS Page 6 of 7



PE-CONJUGATED MONOCLONAL ANTIBODY EFFECTIVE DATE: 2015-12-21

Component CAS # Revision Date Sodium azide 26628-22-8 2007-07-01

Pennsylvania Right To Know Components

Component CAS # Revision Date Sodium azide 26628-22-8 2007-07-01

California Prop. 65 Components

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

15.2 EU

This SDS was prepared in accordance with Regulation (EC) No.1272/2008 and European Directive 67/548/EEC as amended.

15.3 Canada

Not WHMIS controlled

This SDS was prepared in accordance with Hazardous Products Regulations (HPR) and WHMIS 2015.

16 Other Information

16.1 Prepared by: Quality Control, STEMCELL Technologies Inc.

16.2 Revision: N/A

16.3 Notice: The above information is believed to be correct but does not purport to be all

inclusive and shall be used only as a guide. STEMCELL Technologies Inc. shall not be held liable for any damage resulting from handling or from contact with the product. The information contained in this Safety Data Sheet (SDS) is current as of the Effective Date shown in this document and may be subject to

amendment by STEMCELL Technologies Inc.

16.4 Disclaimer: THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT INTENDED FOR

HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES.